FTO and breast carcinoma: In human epidermal growth factor receptor 2 (HER2)-positive breast cancer, it is reported that m6A “eraser” FTO inhibits miR-181b-3p and upregulates the expression of oncogenic ARL5B (Xu et al., 2020b).